Hoth Therapeutics

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The new wholly owned subsidiary will screen for rare disease therapeutics. NEW YORK , Oct. 5, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced, its initiative to utilize Artificial Intelligence to both screen its current pipeline as well as utilize AI for licensing opportunities in acquiring or partnering novel therapeutics for rare diseases.

Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery

NEW YORK , Oct. 2, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the Pre-IND meeting requested on September 8 th for HT-KIT with the U.S. Food and Drug Administration (FDA) has been granted to receive written responses only from the FDA that are targeted for delivery on November 7, 2023. HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting and already has Orphan Drug Designation from the FDA.

FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients

NEW YORK , Sept. 15, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) ("Hoth" or the "Company"), a patient-focused biopharmaceutical company, today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, for the purchase and sale of 1,100,000 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.63 per share of common stock (or common stock equivalent in lieu thereof).

Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

NEW YORK , Sept. 13, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive agreement for the purchase and sale of 1,100,000 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.63 per share of common stock (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules.

Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Gastrointestinal Stromal Tumors Cells Rapidly Died Between 48 and 72 Hours After Exposure to HT-KIT. HT-KIT Shows Positive Results in AML Positive Preclinical Results of Novel HT-KIT Therapeutic Performed at NC State University NEW YORK , Sept.

Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia

HT-KIT received Orphan Drug Designation from FDA for its mRNA Frame Shifting Cancer Therapeutic Hoth intends to initially target mast cell neoplasms for development of HT-KIT, which is a rare, aggressive cancer with poor prognosis NEW YORK , Sept. 11, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has submitted a request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for HT-KIT, a new molecular entity, for the treatment of advance systemic mastocytosis (AdvSM).

Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients

78% of patients reported that their overall health had improved since starting BioLexa as compared to 22% stating that there was no change in their health, or their health was worse. DLQI found that BioLexa use led to a 46% improvement in patient quality of life whereas placebo had no effect.

Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa

HT-ALZ Showed Improvement on Several Tests of Cognitive Function HT-ALZ Showed Positive Benefits with Reductions in Anxiety Completed Dose Response Study Leads Hoth to Begin Formulation Development NEW YORK , Aug. 9, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that HT-ALZ, a therapeutic in development for the treatment of Alzheimer's Disease ("AD"), achieved positive preclinical end points in a study conducted at Washington University, St. Louis. Subjects treated with HT-ALZ show improvement on several tests of cognitive function, including spatial learning and memory, sensorimotor gating, and contextual associative memory.

Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease

NEW YORK , July 25, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that the first patient has been dosed in its Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). Robb Knie, Chief Executive Officer of Hoth Therapeutics, stated, "There is a significant unmet need for treatment for people undergoing EGFR inhibitor therapy and experiencing side effects.

Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical Trial

FDA Approved Trial Now Has Two Sites Approved with Additional Sites in Approval Process Recruitment of Patients to Accelerate NEW YORK , July 19, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has received approval from the Food & Drug Administration ("FDA") for a protocol change in its Phase 2a clinical trial of HT-001. Participants will apply HT-001 Gel once per day for 6 weeks, during which the effect on treating acneiform rash and other skin disorders induced by EGFRI therapy will be evaluated using different assessment tools to measure severity of rash, pain, and itching (pruritus), as well as the change in quality of life.

Hoth Therapeutics Receives Protocol Approval for HT-001 Cancer Therapeutic

Hoth achieves milestone of multiple sites to host trial NEW YORK , June 14, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that it has received written approval from the University of Texas MD Anderson Cancer Center Institutional Review Board (IRB) to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). "We are very pleased to have received IRB Approval for our FIH clinical trial," said Hoth Therapeutics Chief Executive Officer, Robb Knie.

Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical Site

Hoth Therapeutics (NASDAQ: HOTH ) stock is rocketing higher on Tuesday thanks to the company announcing positive results from a preclinical trial. According to a Hoth Therapeutics press release, these results come from its study of HT-ALZ as a treatment for Alzheimer's disease.

Why Is Hoth Therapeutics (HOTH) Stock Up 83% Today?

Higher Dosing Shows Positive Effects on Cognitive Function NEW YORK , June 6, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical  company, today announced that HT-ALZ a therapeutic in development for the treatment of Alzheimer's disease achieved positive preclinical results that outpaced its pervious study.  In particular, the higher dose appears to be most beneficial in a spatial memory test performed at Washington University in St Louis.

Hoth Therapeutics Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's Disease

Hoth to Concentrate on its Current Pipeline and Continue Phase 2 Clinical Study Hoth Has Over Twelve Months Cash on Balance Sheet NEW YORK , May 12, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that they have entered into a mutual agreement with Algorithm Sciences, Inc. ("Algorithm") to terminate their previously announced decision to merge, originally announced on April 26, 2023. After further discussions and review, both Hoth and Algorithm have determined that a definitive merger agreement cannot be reached and it is in the best interest of both companies to terminate the letter of intent and continue to operate as separate companies.

Hoth Therapeutics and Algorithm Sciences Terminate Letter of Intent to Merge

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Hoth Therapeutics, Inc. (NasdaqCM: HOTH) with Algorithm Sciences, Inc. pursuant to which Hoth shareholders are currently anticipated to own approximately 14% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues.

HOTH THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Hoth Therapeutics, Inc. - HOTH

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Hoth Therapeutics, Inc. (NASDAQ: HOTH) and Algorithm Sciences, Inc. is fair to Hoth shareholders. Upon completion of the proposed transaction, Hoth shareholders are expected to own approximately 14% of the combined company. Halper Sadeh encourages Hoth shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-.

HOTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Hoth Therapeutics, Inc. Is Fair to Shareholders

Anthony Zook, formerly of Astra Zeneca, to be named Chairman of The Board Mike Tilton to be named Chief Executive Officer of the Combined Company Algorithm pipeline focused on Pulmonary Arterial Hypertension (PAH) a rare disease with a prevalence of ~100,000 patients in the US NEW YORK , April 26, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced it has signed a Letter of Intent to merge with Algorithm Sciences, Inc. ("Algorithm") a company focused on Pulmonary Arterial Hypertension (PAH).  The combined company will be named Algorithm Sciences, Inc. and be led by experienced biopharma executives, including Mike Tilton as CEO, David Cavalier as CFO and Anthony Zook, Algorithm's current chairman of the board, who will be nominated as chairman of the combined company's board of directors.

Hoth Therapeutics and Algorithm Sciences Execute Letter of Intent to Merge

NEW YORK , March 8, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the activation of Washington University School of Medicine in St. Louis as the first clinical site in the CLEER-001 Phase 2a clinical trial of HT-001 for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer.

Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

Terran Orbital Corp

Southwestern Energy

Are penny stocks worth investing in? The post Are Penny Stocks Worth the Risk?

Are Penny Stocks Worth the Risk? 3 Reasons Why They Could Be

Strengthens Measures to Safeguard Shareholder Interests through ShareIntel's Investigation and Due Diligence Services for Illegal Short Selling NEW YORK , Feb. 16, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a service agreement with Shareholder Intelligence Services, LLC ("ShareIntel"), a patented compliance driven SAAS retained by public companies to track shareholder ownership and monitor critical broker-dealer and shareholder movement, to investigate and report on potential illegal naked short selling activities of Company stock (HOTH), among other potential trading violations. "We believe this collaboration with ShareIntel will be value added by allowing Hoth to better monitor trading activity, including broker-dealer, clearing firm, and shareholder position management," said Robb Knie, Chief Executive Officer.

Hoth Therapeutics Retains ShareIntel to Investigate Illegal Naked Shorting Activity

HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model and Results Show Reduced Anxiety and Improved Performance NEW YORK , Feb. 8, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused  biopharmaceutical company,  today announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model (aged APP/PS1+/- mice), supporting the therapeutic cognitive potential of HT-ALZ after chronic oral dosing of 20mg/kg and 40mg/kg of HT-ALZ  The research was conducted as part of the company's Sponsored Research Agreement with Washington University in St. Louis.  HT-ALZ  is a therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of dementia related to  Alzheimer's disease  (AD).

Hoth Therapeutics Announces Increased Positive Results of its Alzheimer's Therapeutic HT-ALZ

Patient Recruitment Underway NEW YORK , Jan. 25, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical  company, today announced that it has selected 3 of its clinical sites for its Phase 2a clinical trial for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer.

Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

NEW YORK , Jan. 3, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company" or "Hoth"), a patient-focused biopharmaceutical company, today announced the closing of its previously announced private placement of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase shares of common stock priced at-the-market under Nasdaq rules, resulting in gross proceeds to the Company of $10 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company sold and issued 2,000,000 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,500,000 shares of common stock in the private placement, at a purchase price of $5.00 per share and accompanying warrants.

Hoth Therapeutics Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Hoth Therapeutics Inc HOTH shares are trading lower by 21.22% to $8.44 Friday morning after the company announced a $10 million private placement priced at-the-market under Nasdaq rules.

Why Hoth Therapeutics Shares Are Nosediving - Hoth Therapeutics (NASDAQ:HOTH)

NEW YORK , Dec. 29, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,000,000 shares of its common stock (or common stock equivalent in lieu thereof) and warrants to purchase up to an aggregate of 2,500,000 shares of common stock, at a purchase price of $5.00 per share and accompanying warrant in a private placement priced at-the-market under Nasdaq rules. The gross proceeds to the Company from the private placement are expected to be $10 million, before deducting the placement agent's fees and other offering expenses payable by the Company.

News for Hoth Therapeutics Stock (HOTH)